Key result
Omentin-1 is an adipokine with potential atheroprotective and anti-inflammatory effects that may serve as a therapeutic target in metabolic-related disorders.
Why the study?
Omentin may exert atheroprotective, anti-inflammatory, and metabolic benefits, motivating a review of its potential therapeutic targets in metabolic-related disorders.
This review highlights omentin-1 as a potential therapeutic target for metabolic-related disorders due to its atheroprotective and anti-inflammatory properties.
Answers are grounded in this paper and cite their sources.
Omentin-1 merits investigation as a therapeutic target in metabolic disorders; leaves open validation in prospective trials before clinical consideration.
Omentin is an adipokine mainly produced by visceral fat tissue, and it has two isoforms: omentin-1 and omentin-2. Omentin-1 is predominantly secreted by visceral adipose tissue, deriving specially from the stromal vascular fraction cells of white adipose tissue (WAT). Levels of omentin-1 are also expressed in other WAT depots, like epicardial adipose tissue. Omentin-1 exerts several beneficial effects in glucose homeostasis in obesity and diabetes. In addition, research has suggested that omentin may have atheroprotective (protective against the development of atherosclerosis) and anti-inflammatory effects, potentially contributing to cardiovascular health. This review highlights the potential therapeutic targets of omentin-1 in metabolic-related disorders.
No takes yet. Share an insight, caveat, or question.
Cristina M. Sena (2023) conducted a review in Metabolic-related disorders and cardiovascular health. Omentin-1 was evaluated. Omentin-1 is an adipokine with potential atheroprotective and anti-inflammatory effects that may serve as a therapeutic target in metabolic-related disorders.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: